Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00842309 · ClinicalTrials.gov registry record · Early Phase 1
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 68
- Enrollment target
NCT00842309: Completed Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00842309 is a Early Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 68 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00842309, a Early Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of the study is to conduct a double-blind, placebo-controlled study of D-cycloserine (DCS) augmentation of behavior therapy in individuals with Body Dysmorphic Disorder (BDD). Specifically, we intend to randomize 50 individuals with BDD to receive either DCS (n = 25) or placebo (n = 25) one hour prior to 8 of 10 behavior therapy sessions.
Primary Outcome
The BDD-YBOCS is the gold-standard, semi-structured clinician-administered assessment of BDD severity. It contains 12 items ranging from 0 to 4, which are summed to generate a total score (range = 0 to 48). Higher scores indicate more severe BDD symptoms. The BDD-YBOCS will be used to assess BDD symptoms at baseline and endpoint.
Interventions
- DRUG Placebo
- DRUG d-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2008-11 |
| Est. Completion | 2018-08 |
| Phase | Early Phase 1 |
What the finished NCT00842309 record still lists
NCT00842309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00842309 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00842309 about?
NCT00842309 is a clinical study titled "D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder". The purpose of the study is to conduct a double-blind, placebo-controlled study of D-cycloserine (DCS) augmentation of behavior therapy in individuals with Body Dysmorphic Disorder (BDD). Specifically, we intend to randomize 50 individuals with BDD to receive either DCS (n = 25) or placebo (n = 25) ...
What is the current status of trial NCT00842309?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 68 participants. The study started on 2008-11. Estimated completion is 2018-08.
What interventions are being tested in trial NCT00842309?
The interventions under investigation include: Placebo (DRUG), d-cycloserine (DRUG).
Who is sponsoring clinical trial NCT00842309?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00842309's enrollment target sits among peer trials
68 357th of 2000 higher than 1,640 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia